The effect of urtica dioica on vaginal atrophy

Recruitment & Eligibility

Status: Pending

Sex: Female

Target Recruitment: 102

Inclusion Criteria

Iranian and resident of gorgan
Satisfaction to participate in the study
Literacy for reading and writing
Married and sexually active in the past 6 months
Normal menopause
Age 45-60
Normal pap smear
Diagnosis of vaginal atrophy (score of 4 or more on the vaginal atrophy questionnaire and vaginal PH greater than 5 and VMV equal to or less than 55)

Exclusion Criteria

Use of phytoestrogens (soy, flaxseed, red clover, fennel, nettle) one month before the start of the study
Hormone therapy for 6 months before the start of the study
Abnormal vaginal bleeding (spotting, pink or brown discharge, or obvious bleeding)
Specific medical diseases (history of ovarian, breast and endometrial cancer - cardiovascular disease - history of thromboembolism or thrombophlebitis - history of coagulation diseases - history of ischemic stroke - migraine headaches - seizures - uterine leiomyoma - endometriosis - hypertension - diabetes - hyperlipidemia- liver and gallbladder disease - chronic kidney disease - tobacco use history - genitourinary abnormalities (uterine unicorn, bicornuate, double and septate)
Use of certain medications (hormonal medications - moisturizers and vaginal gels - antihypertensive drugs - diuretics - antidepressants - antipsychotics - lithium - antihistamines - barbiturates - narcotics - benzodiazepines - hallucinogens - amphetamine – cocaine- digoxin)
Vaginal infections (candida-trichomonas-bacterial vaginosis-std-herpes)
History of estrogen sensitivity (breast pain, breast tenderness and sensation, spotting, itching, burning, redness)
History of nettle sensitivity

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mental symptoms of vaginal atrophy. Timepoint: Before the study, 4 and 8 weeks after the intervention. Method of measurement: Vaginal assessment scale.;Vaginal PH. Timepoint: Before the study, 4 and 8 weeks after the intervention. Method of measurement: PH-indicator strips.;Vaginal maturation index. Timepoint: Before the study, 4 and 8 weeks after the intervention. Method of measurement: Pathological examination.;Vaginal maturation value. Timepoint: Before the study, 4 and 8 weeks after the intervention. Method of measurement: Pathological examination.

Secondary Outcome Measures

Name	Time	Method
The sexual quality of life. Timepoint: Before the study, 4 and 8 weeks after the intervention. Method of measurement: The sexual quality of life female questionaire.